Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Community-acquired Pneumonia Clinical Trial

Official title:

Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02555852
• Other study ID #: CNODES_DEMO-2
• Status: Completed
• Phase: N/A
• First received: September 18, 2015
• Last updated: September 18, 2015
• Start date: September 2011
• Est. completion date: February 2012

Study information

• Verified date: September 2015
• Source: Canadian Network for Observational Drug Effect Studies, CNODES
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of the study is to determine whether proton pump inhibitors (PPIs), a medication used to treat gastric conditions, increase the risk of hospitalization for community-acquired pneumonia (HCAP).

The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada, the US, and the UK. Cohort entry will be defined by the initiation of an oral non-steroidal anti-inflammatory drug, with follow-up until hospitalization for pneumonia or end of follow-up (6 months). The results from the separate sites will be combined using a statistical approach called meta-analysis to provide an overall assessment of the risk of HCAP with PPIs.

Description:

Previous observational studies have found an association between proton pump inhibitors (PPIs), a class of medications used to treat gastric conditions, and the risk of community acquired pneumonia. These studies, however, had important limitations including confounding by indication and protopathic bias. The purpose of this study is to determine whether PPIs increase the risk of hospitalization for community-acquired pneumonia (HCAP). To overcome the limitations of previous studies that examined this issue, this study will be conducted in a cohort of new users of non-steroidal anti-inflammatory drugs (NSAIDs), in whom PPIs are often prescribed prophylactically to prevent dyspepsia and other gastric side effects.

The investigators will use a common-protocol approach to conduct retrospective cohort studies using administrative health care data from eight jurisdictions (the Canadian provinces of Alberta, Saskatchewan, Manitoba, Ontario, Quebec, and Nova Scotia, as well as the United States (US) MarketScan, and the United Kingdom (UK) General Practice Research Database [GPRD]). Briefly, the Canadian databases include population-level data on physician billing, diagnoses and procedures from hospital discharge abstracts, and dispensations for prescription drugs. Alberta, Nova Scotia, Ontario, and Quebec data will be restricted to patients aged 65 years and older as prescription data are not available for younger patients. For Quebec, a 10% random sample of eligible patients will be used. The GPRD is a clinical database that is representative of the UK population and contains the records for patients seen at over 680 general practitioner practices in the UK. US MarketScan includes individuals and their dependents covered by large U.S. employer health insurance plans, and government and public organizations. As Medicare eligibility begins for those above the age of 65, the US MarketScan data will be restricted to patients aged 40 to 65 years in order to ensure complete data capture.

In each jurisdiction, the investigators will assemble a source population that includes all patients with a prescription for an oral NSAID (WHO Anatomical Therapeutic Chemical (ATC) Code M01A). From this source population, a study cohort will be created including all patients who received a prescription for an oral NSAID of ≥ 30 days duration, as patients receiving short duration prescriptions are unlikely to be prescribed a PPI for prophylactic reasons. The date of prescription (for the GPRD) or dispensation (for all other sites) of the oral NSAID will define the date of study cohort entry.

Patients will be followed from the date of study cohort entry until an event (defined below) or censoring due to death, departure from the database, end of follow-up (180 days), or the end of the study period (September 30, 2011 or the last date of data availability at that site), whichever occurs first. Patients will be permitted to enter the cohort multiple times provided that all inclusion criteria are met.

The investigators will create three mutually exclusive exposure categories: 1) PPI users, 2) H2RA users, and 3) unexposed patients. The investigators will use an analysis analogous to an intention-to-treat approach. Exposure to PPIs will be defined as a prescription for a PPI (esomeprazole, omeprazole, pantoprazole, lansoprazole, rabeprazole) on the same day as their cohort entry defining prescription for an NSAID. Exposure to H2RAs will be defined as a prescription for a H2RA (cimetidine, ranitidine, famotidine, nizatidine, niperotidine, roxatidine, ranitidine bismuth citrate, lafutidine, cimetidine combinations, and famotidine combinations) on the same day as their cohort entry defining prescription for an NSAID. Patients that are considered to be unexposed will be defined as patients not prescribed a PPI or H2RA on the same day as their cohort entry defining prescription for an NSAID. The primary outcome will be defined as incident HCAP during the 6 months following initiation of NSAID therapy.

Multiple logistic regression will be used to estimate site-specific adjusted odds ratios (aORs) and corresponding 95% confidence intervals (CIs) for the association of incident HCAP at 6 months and PPI exposure. This is considered the primary analysis. Several sensitivity analyses will be performed to assess the robustness of study results. Such analyses include: restricting analyses to a single, random, observation per patient; excluding patients who received a prescription for a PPI, H2RA, or NSAID in the 12 months before cohort entry; and excluding crossovers between PPI and H2RAs. High dimensional propensity scores will be estimated for all patients in the cohort using logistic regression. Finally, all site-specific estimates will be meta-analyzed using fixed models with inverse variance weighting. The amount of between-site heterogeneity will be estimated using the I-squared statistic.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4238504
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Patients with a first oral NSAID prescription

• Patients at least 40 years of age (except Alberta, Ontario, and Nova Scotia, where patients will be at least 66 years of age)

• Patients with at least 1 year of history in the database.

Exclusion Criteria:

• Patients aged < 40 years at cohort entry (or < 66 in Alberta, Ontario, and Nova Scotia)

• Received a prescription for a PPI, a H2RA, or a NSAID (any route of administration) in the 6 months prior to cohort entry

• Had an HCAP (ICD-9-CM code (in any field): 480.x-487.x; ICD-10-CA code: J10.0 - J18.9) or an extended emergency room visit for community-acquired pneumonia in the year prior to cohort entry (where available)

• Hospitalized at the time of cohort entry

• Received a prescription for medications used for the treatment of tuberculosis (ATC Code J04A) (where available)

• Had a history of cancer (other than non-melanoma skin cancer) in the year prior to cohort entry

• Hospitalized >3 days within the 30 days before cohort entry

• Had <1 year of continuous observation time in the database prior to cohort entry

Related Conditions & MeSH terms

• Community-acquired Pneumonia
• Gastroesophageal Reflux
• Gastroesophageal Reflux Disease (GERD)
• Pneumonia

Intervention

Drug:
• esomeprazole
Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a = 30 day NSAID prescription.
• omeprazole
Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a = 30 day NSAID prescription.
• pantoprazole
Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a = 30 day NSAID prescription.
• lansoprazole
Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a = 30 day NSAID prescription.
• rabeprazole
Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a = 30 day NSAID prescription.
• cimetidine
Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a = 30 day NSAID prescription.
• ranitidine
Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a = 30 day NSAID prescription.
• famotidine
Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a =30 day NSAID prescription.
• nizatidine
Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a = 30 day NSAID prescription.
• niperotidine
Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a = 30 day NSAID prescription.
• roxatidine
Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a = 30 day NSAID prescription.
• ranitidine bismuth citrate
Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a = 30 day NSAID prescription.
• lafutidine
Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a = 30 day NSAID prescription.
• cimetidine combinations
Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a = 30 day NSAID prescription.
• famotidine combinations
Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a = 30 day NSAID prescription.

Locations

Country	Name	City	State
Canada	Lady Davis Institute for Medical Research, Jewish General Hospital	Montreal	Quebec

Sponsors (3)

Lead Sponsor	Collaborator
Canadian Network for Observational Drug Effect Studies, CNODES	Canadian Institutes of Health Research (CIHR), Drug Safety and Effectiveness Network, Canada

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, Teare GF, Ravani P, Ernst P, Dormuth CR; CNODES Investigators. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-a — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hospitalization for Community-Acquired Pneumonia (HCAP)	HCAP during the 6 months following cohort entry; Patients with HCAP with any of the following diagnostic codes: ICD-9: 487.0, 487.1, 487.0, 487.1, 487.0, 480.9, 481.x, 482.2, 482.0, 482.1, 482.30, 482.31, 482.32, 482.39, 482.40, 482.41, 482.42, 482.49, 482.81, 482.82, 482.83, 482.89, 482.9, 483.0, 484.7, 484.8, 485.X, 481.X, 486.X ; ICD-10: J10.0, J11.0, J11.1, J12.9, J13, J14, J15.X, J16.8, J17.0, J17.2, J17.3, J17.8, J18.0, J18.1, J18.8, J18.9.	Patients will be followed from the date of study cohort entry until HCAP, censoring, or for up to 6 months.

External Links

•   This organization's website describing general functions, other CNODES projects, and investigator profiles.